This study is testing a combination of two FDA-approved drugs, pembrolizumab (Keytruda) and pemetrexed (Alimta), for people with chordoma that is getting worse. While these drugs are approved for other cancers, they are not yet approved for chordoma. The study will use a higher dose of pemetrexed than typically approved to see if it's more effective for chordoma. Researchers want to see how many people respond to the treatment, how safe it is, and how it affects quality of life. You may be able to join if you are 18 or older, can understand and sign a consent form, and are willing to follow all study procedures. The study aims to enroll 21 participants.

Study design

This is an interventional study with a planned enrollment of 21 participants. It is testing the effectiveness and safety of a drug combination.

What's involved

You would receive pembrolizumab and pemetrexed by IV infusion on Day 1 of each 21-day treatment cycle, along with supportive medications. Outcome measures will be monitored until disease progression, through study completion (estimated average of 2 years), or withdrawal from the study.

Compensation

Not stated in the trial record.

Follow-up

Outcome measures will be monitored until disease progression, through study completion (estimated average of 2 years), or withdrawal from the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.